Sharon Benzeno Adaptive Biotechnologies Corp (ADPT) insider trading activity

Sharon Benzeno is Chief Commercial Ofc Imm Med of Adaptive Biotechnologies Corp. Currently has a direct ownership of 296,791 shares of ADPT, which is worth approximately $4.18 Million. The most recent transaction as insider was on Dec 04, 2025, when has been sold 12,604 shares (Common Stock) at a price of $16.85 per share, resulting in proceeds of $212,377. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 297K

24.43% 3M change

9.35% 12M change

Total Value Held $4.18 Million

SHARON BENZENO Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 04 2025	SELL Open market or private sale	$212,377 $16.85 p/Share	12,604 Reduced 4.07%	296,791 Common Stock
Dec 04 2025	BUY Exercise of conversion of derivative security	$103,352 $8.2 p/Share	12,604 Added 3.91%	309,395 Common Stock
Nov 21 2025	SELL Open market or private sale	$5,216,346 $16.91 p/Share	308,477 Reduced 50.97%	296,791 Common Stock
Nov 21 2025	BUY Exercise of conversion of derivative security	$2,199,441 $7.13 p/Share	308,477 Added 33.76%	605,268 Common Stock
Nov 20 2025	SELL Open market or private sale	$4,927,679 $16.54 p/Share	297,925 Reduced 50.1%	296,791 Common Stock
Nov 20 2025	BUY Exercise of conversion of derivative security	$2,080,527 $10.3 p/Share	201,993 Added 25.35%	594,716 Common Stock
Mar 05 2025	SELL Open market or private sale	$312,208 $6.99 p/Share	44,665 Reduced 10.21%	392,723 Common Stock

Mar 04 2025	BUY Grant, award, or other acquisition	-	109,973 Added 20.09%	437,388 Common Stock
Mar 05 2024	SELL Open market or private sale	$101,101 $3.44 p/Share	29,390 Reduced 8.24%	327,415 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	132,979 Added 27.15%	356,805 Common Stock
Mar 06 2023	SELL Open market or private sale	$100,688 $8.57 p/Share	11,749 Reduced 4.99%	223,826 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	132,979 Added 36.08%	235,575 Common Stock
Mar 07 2022	SELL Open market or private sale	$32,067 $12.01 p/Share	2,670 Reduced 2.54%	102,596 Common Stock
Mar 04 2022	BUY Grant, award, or other acquisition	-	82,372 Added 43.9%	105,266 Common Stock
Mar 15 2021	SELL Open market or private sale	$56,245 $41.54 p/Share	1,354 Reduced 5.58%	22,894 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$42,935 $31.71 p/Share	1,354 Added 5.29%	24,248 Common Stock
Mar 04 2021	BUY Grant, award, or other acquisition	-	22,894 Added 50.0%	22,894 Common Stock
Mar 01 2021	SELL Open market or private sale	$391,838 $57.87 p/Share	6,771 Reduced 100.0%	0 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	$45,975 $6.79 p/Share	6,771 Added 50.0%	6,771 Common Stock
Feb 19 2021	SELL Open market or private sale	$25,459 $61.2 p/Share	416 Reduced 100.0%	0 Common Stock
Feb 19 2021	BUY Exercise of conversion of derivative security	$2,608 $6.27 p/Share	416 Added 50.0%	416 Common Stock
Feb 16 2021	SELL Open market or private sale	$1,046,988 $64.43 p/Share	16,250 Reduced 100.0%	0 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$515,287 $31.71 p/Share	16,250 Added 50.0%	16,250 Common Stock
Feb 01 2021	SELL Open market or private sale	$379,188 $56.01 p/Share	6,770 Reduced 100.0%	0 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$45,968 $6.79 p/Share	6,770 Added 50.0%	6,770 Common Stock

Sharon Benzeno

Chief Commercial Ofc Imm Med

Seattle, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Value

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT

Account